ArticleTranslational andrology and urology2025
Pathologic characteristics and management strategies for two categories of prostate cancer patients with low prostate-specific antigen undergoing radical prostatectomy.
Article in Translational andrology and urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Prostate cancer (PCa) with low levels of prostate-specific antigen (PSA) (0-4 ng/mL) includes PCa detected through biopsy and incidental PCa (IPC) in patients with previous prostate surgeries. The study was conducted to compare these two groups of patients undergoing radical prostatectomy (RP), aiming to assess pathological characteristics and suggest strategies for predicting and managing low PSA PCa. Methods: A retrospective analysis was performed on two categories of low PSA PCa patients. Baseline characteristics, PSA density (PSAD), preoperative multiparametric magnetic resonance imaging (mpMRI) for RP, preoperative and postoperative pathological data, and biochemical recurrence (BCR) were evaluated. Results: Fifty patients were analyzed. There were 80% of tumors being clinically significant and in early-stage, indicating a favorable prognosis for most low PSA PCa patients, and the use of preoperative androgen deprivation therapy (ADT) treatment may be beneficial for a small subset of patients with advanced tumors. Patients with low PSA and IPC history had lower PSA levels, PSAD, and prostate volume, however, BCR rates did not significantly differ between low PSA patients with and without IPC history. mpMRI and PSAD demonstrated potential in predicting PCa in low PSA cases. Conclusions: Predicting low PSA PCa remains challenging, but mpMRI and PSAD could be valuable predictors. Both low PSA groups showed a likelihood of clinical significance, with favorable pathological features. Early diagnosis and treatment are crucial, especially for aggressive IPC PCa tumors. Reevaluating PSA thresholds is vital to avoid missed or misdiagnosed low PSA cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.